BCMA
A BCMA-directed mRNA cell therapy approach showed durable responses in myasthenia gravis. Anti-BCMA CAR T targets the effector population that CD19-targeted therapy cannot reach. BCMA is expressed on plasma cells, including long-lived bone…
1 sources - 4 claims
A BCMA-directed mRNA cell therapy approach showed durable responses in myasthenia gravis. Anti-BCMA CAR T targets the effector population that CD19-targeted therapy cannot reach. BCMA is expressed on plasma cells, including long-lived bone marrow-resident plasma cells. Anti-BCMA CT103A has been evaluated in AQP4-IgG seropositive NMOSD and progressive multiple sclerosis.